Study Title
A multi-center, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with Covid-19 following discharge. (Activ)
Purpose
To determine if a blood thinner medication can prevent blood clots from developing in patients recently hospitalized with Covid-19.
Eligibility
Criteria:
1. Have been hospitalized for COVID-19 infection for 48 or more hours and enrolled prior to discharge.
2. Have a COVID-19 positive test within 2 weeks of hospital admit date.
3. Must be 18 years or older.
You cannot:
1. Have an existing indication for anticoagulation.
2. Have a contraindication to antithrombotic therapy.
- Ischemic stroke, intracranial bleed, or neurosurgery within 3 months
- Known bleeding within the last 30 days requiring emergency room presentation or hospitalization
- Known major surgery within 14 days
- Inherited or acquired bleeding disorder
3. Have a low platelet count or hemoglobin.
4. Be pregnant
5. Have a life expectancy less than 90 days.
Study Process
1. Study treatment provided at time of discharge.
2. Call center will contact you periodically for data collection.
3. Participation last 13 weeks.
Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130
Trial Details
Investigator:
Anthony Stuart, MD
IRB:
WIRB
IRB Number:
Trial Type:
Drug
Sponsor:
Duke University
Contact Information:
(318) 212-8130